Gainers
• Immutep, Inc. IMMP shares increased by 65.45% to $1.82 during Wednesday's pre-market session.
• RTI Surgical Hldgs, Inc. RTIX shares increased by 20.35% to $4.08.
• Acorda Therapeutics, Inc. ACOR shares moved upwards by 18.57% to $0.83. The most recent rating by H.C. Wainwright, on May 6, is at Neutral, with a price target of $5.
• Moderna, Inc. MRNA shares increased by 16.87% to $87.70. The most recent rating by Brookline Capital, on Jul 13, is at Buy, with a price target of $95.
• TherapeuticsMD, Inc. TXMD stock moved upwards by 16.10% to $1.73. According to the most recent rating by JP Morgan, on May 19, the current rating is at Neutral.
• VBI Vaccines, Inc. VBIV stock moved upwards by 14.85% to $5.18.
• Novan, Inc. NOVN shares rose 10.80% to $0.56.
• Fluidigm, Inc. FLDM stock increased by 9.42% to $5.92.
• Orchard Therapeutics, Inc. ORTX stock moved upwards by 9.37% to $5.60.
• ReWalk Robotics, Inc. RWLK shares increased by 8.40% to $1.29.
Losers
• Zynex, Inc. ZYXI stock decreased by 11.14% to $23.30 during Wednesday's pre-market session. According to the most recent rating by B. Riley FBR, on Jul 13, the current rating is at Neutral.
• Endologix, Inc. ELGX stock declined 10.73% to $0.26. According to the most recent rating by BTIG, on May 12, the current rating is at Neutral.
• IMV, Inc. IMV stock declined 8.86% to $4.22. The most recent rating by Wells Fargo, on May 18, is at Overweight, with a price target of $8.
• Cleveland BioLabs, Inc. CBLI stock fell 8.26% to $3.
• Myos Rens Technology, Inc. MYOS stock fell 7.76% to $1.19.
• Dynatronics, Inc. DYNT stock declined 6.69% to $0.77. The most recent rating by Aegis Capital, on May 19, is at Buy, with a price target of $1.
• Rigel Pharmaceuticals, Inc. RIGL stock declined 6.67% to $3.85. The most recent rating by JP Morgan, on May 27, is at Overweight, with a price target of $6.
• Dare Bioscience, Inc. DARE shares fell 6.58% to $1.42. The most recent rating by Brookline Capital, on Apr 28, is at Buy, with a price target of $8.
• Vaxart, Inc. VXRT shares declined 5.13% to $16.10. The most recent rating by B. Riley FBR, on Jul 13, is at Buy, with a price target of $22.
• INmune Bio, Inc. INMB shares declined 5.08% to $14.95. The most recent rating by HC Wainwright & Co., on Jul 15, is at Buy, with a price target of $20.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.